Central and peripheral nervous system toxicity of common chemotherapeutic agents

Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9–17

Weng TI, Shih FF, Chen WJ (2004) Unusual causes of hyperammonemia in the ED. Am J Emerg Med 22:105–107

Dietrich J, Marienhagen J, Schalke B, Bogdahn U, Schlachetzki F (2004) Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide. Ann Pharmacother 38:242–246

Patten SB (2006) Psychiatric side effects of interferon treatment. Curr Drug Saf 1:143–150

Kovacs A, Szomor A, Abraham I, Nagy F, Losonczy H (2002) Psychiatric sequelae of interferon-alpha therapy. Orv Hetil 143:2183–2187

Bannink M, Kruit WH, Van Gool AR, Sleijfer S, van der Holt B, Eggermont AM, Stoter G, Hengeveld MW (2008) Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated. Psychosomatics 49:56–63

Meyers CA, Scheibel RS, Forman AD (1991) Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 41:672–676

Jaksic W, Veljkovic D, Pozza C, Lewis I (2004) Methotrexate-induced leukoencephalopathy reversed by aminophylline and high-dose folinic acid. Acta Haematol 111:230–232

Linnebank M, Malessa S, Moskau S, Semmler A, Pels H, Klockgether T, Schlegel U (2007) Acute methotrexate-induced encephalopathy–causal relation to homozygous allelic state for MTR c.2756A>G (D919G)? J Chemother 19:455–457

Renard D, Westhovens R, Vandenbussche E, Vandenberghe R (2004) Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 251:226–228

Terasawa Y, Nakane S, Ohnishi T, Harada M, Furutani K, Izumi Y, Kaji R (2007) Case of methotrexate encephalopathy: findings on diffusion tensor image and correlation with clinical outcome. Rinsho Shinkeigaku 47:79–84

Eichler AF, Batchelor TT, Henson JW (2007) Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro Oncol 9:373–377

Lai R, Abrey LE, Rosenblum MK, DeAngelis LM (2004) Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology 62:451–456

Riga M, Psarommatis I, Korres S, Varvutsi M, Giotakis I, Apostolopoulos N, Ferekidis E (2007) Neurotoxicity of vincristine on the medial olivocochlear bundle. Int J Pediatr Otorhinolaryngol 71:63–69

Hurwitz RL, Mahoney DH Jr, Armstrong DL, Browder TM (1988) Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol 16:216–219

Toker E, Yenice O, Ogut MS (2004) Isolated abducens nerve palsy induced by vincristine therapy. J AAPOS 8:69–71

Fleming RA (1997) An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 17:146S–154S

David KA, Picus J (2005) Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol 28:277–280

Kilickap S, Cakar M, Onal IK, Tufan A, Akoglu H, Aksoy S, Erman M, Tekuzman G (2006) Nonconvulsive status epilepticus due to ifosfamide. Ann Pharmacother 40:332–335

Park IS, Lee HJ, Lee YS, Hwang JS, Lee MS (2005) Ifosfamide-induced encephalopathy with or without using methylene blue. Int J Gynecol Cancer 15:807–810

Dufour C, Grill J, Sabouraud P, Behar C, Munzer M, Motte J, Oberlin O, Paci A, Hartmann O (2006) Ifosfamide induced encephalopathy: 15 observations. Arch Pediatr 13:140–145

Bartynski WS, Zeigler ZR, Shadduck RK, Lister J (2004) Pretransplantation conditioning influence on the occurrence of cyclosporine or FK–506 neurotoxicity in allogeneic bone marrow transplantation. AJNR Am J Neuroradiol 25:261–269

Mueller AR, Platz KP, Bechstein WO, Schattenfroh N, Stoltenburg-Didinger G, Blumhardt G, Christe W, Neuhaus P (1994) Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 58:155–170

Taque S, Peudenier S, Gie S, Rambeau M, Gandemer V, Bridoux L, Betremieux P, De Parscau L, Le Gall E (2004) Central neurotoxicity of cyclosporine in two children with nephrotic syndrome. Pediatr Nephrol 19:276–280

Teive HA, Brandi IV, Camargo CH, Bittencourt MA, Bonfim CM, Friedrich ML, de Medeiros CR, Werneck LC, Pasquini R (2001) Reversible posterior leucoencephalopathy syndrome associated with bone marrow transplantation. Arq Neuropsiquiatr 59:784–789

Cid J, Revilla M, Cervera A, Cervantes F, Munoz E, Ferrer I, Montserrat E (2000) Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia. Ann Hematol 79:392–395

Saumoy M, Castells G, Escoda L, Mares R, Richart C, Ugarriza A (2002) Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma 43:433–436

Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW (1986) Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res 46:5953–5958

Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF (1986) Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 70:1225–1228

Saito B, Nakamaki T, Nakashima H, Usui T, Hattori N, Kawakami K, Tomoyasu S (2007) Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. Am J Hematol 82:304–306

Vaughn DJ, Jarvik JG, Hackney D, Peters S, Stadtmauer EA (1993) High-dose cytarabine neurotoxicity: MR findings during the acute phase. Am J Neuroradiol 14:1014–1016

Gottlieb D, Bradstock K, Koutts J, Robertson T, Lee C, Castaldi P (1987) The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 60:1439–1441

Vogel H, Horoupian DS (1993) Filamentous degeneration of neurons. A possible feature of cytosine arabinoside neurotoxicity. Cancer 71:1303–1308

Lucato LT, McKinney AM, Short J, Teksam M, Truwit CL (2006) Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity. Australas Radiol 50:364–368

Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR Jr, Grem JL, Allegra CJ, Diasio RB, Chu E (1996) Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2:477–481

Barbieux C, Patri B, Cerf I, de Parades V (1996) Acute cerebellar syndrome after treatment with 5-fluorouracil. Bull Cancer 83:77–80

Saif MW, Wilson RH, Harold N, Keith B, Dougherty DS, Grem JL (2001) Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs 12:525–531

Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP (2008) Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 66:218–228

Verstappen CC, Postma TJ, Geldof AA, Heimans JJ (2004) Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation. Anticancer Res 24:2337–2341

Openshaw H, Beamon K, Synold TW, Longmate J, Slatkin NE, Doroshow JH, Forman S, Margolin K, Morgan R, Shibata S, Somlo G (2004) Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clin Cancer Res 10:461–467

Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P, Kalofonos HP (2006) Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage 32:237–244

Perry JR, Warner E (1996) Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology 46:1596–1599

Mayerhofer K, Bodner K, Saletu B, Bodner-Adler B, Anderer P, Hefler L, Kaider A, Leodolter S, Kainz C (2000) Paclitaxel does not cause central nervous adverse effects: a prospective vigilance-controlled EEG mapping study in ovarian cancer patients. Wien Klein Wochenschr 112:1007–1013

Ziske CG, Schottker B, Gorschluter M, Mey U, Kleinschmidt R, Schlegel U, Sauerbruch T, Schmidt-Wolf IG (2002) Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann.Oncol 13:629–631

von Schlippe M, Fowler CJ, Harland SJ (2001) Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer 85:823–826

Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C, Jandolo B, Cognetti F, Bove L (2003) Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21:927–931

Leonetti C, Biroccio A, Gabellini C, Scarsella M, Maresca V, Flori E, Bove L, Pace A, Stoppacciaro A, Zupi G, Cognetti F, Picardo M (2003) Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int J Cancer 104:243–250

Bove L, Picardo M, Maresca V, Jandolo B, Pace A (2001) A pilot study on the relation between cisplatin neuropathy and vitamin E. J Exp Clin Cancer Res 20:277–280

Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G (1998) Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Am J Neuroradiol 19:415–417

Verschraegen C, Conrad CA, Hong WK (1995) Subacute encephalopathic toxicity of cisplatin. Lung Cancer 13:305–309

Joseph EK, Chen X, Bogen O, Levine JD (2008) Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 9:463–472

Hochster HS, Grothey A, Childs BH (2007) Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25:4028–4029

Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A (2008) Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 26:1188–1189

Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507–1515

Plasmati R, Pastorelli F, Cavo M, Petracci E, Zamagni E, Tosi P, Cangini D, Tacchetti P, Salvi F, Bartolomei I, Michelucci R, Tassinari CA (2007) Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 69:573–581

Zara G, Ermani M, Rondinone R, Arienti S, Doria A (2008) Thalidomide and sensory neurotoxicity: A neurophysiological study. J.Neurol Neurosurg Psychiatry 79:1258–1261

Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507–4514

Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M (2005) Neurological toxicity of long-term (>1 year) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 74:212–216